The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on

ConclusionsThe data generated by the GLAR shows that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp  (a) levels, progressive CVD, and maximally tolerated lipid lowering medication. In addition, LA treatments were found to be safe with a low rate of side effects.
Source: Clinical Research in Cardiology Supplements - Category: Cardiology Source Type: research